Diagnostic System by Luoxis Can Detect Oxidative Stress in MS

Luoxis Diagnostics, Inc. recently presented three clinical and preclinical findings that feature the company’s proprietaryĀ RedoxSYSā„¢ Diagnostic System as a comprehensive, groundbreaking tool for research capable of assessing a patient’sĀ oxidation-reduction potential (ORP) in the event ofĀ injury, illness, or stress.Ā The findings were presented as peer-reviewed posters during the recently concludedĀ …

Newly Identified Immune Cell Sheds Light on Multiple Sclerosis Cause

Researchers from the National University of Singapore have found a new type of immune cell that could aid in the development of treatments for multiple sclerosis (MS). The study was published on November 21 in the journalĀ Cell ResearchĀ entitled, “STAT5 programs a distinct subset of GM-CSF-producing T helper…

Experimental Drug for RRMS, SPMS Enters Phase 2 Trial

Lexington, MA-based biopharmaceutical companyĀ Xenetic Biosciences, Inc.Ā has just announced its new license partnerĀ Pharmsynthez has completed dosing in its ongoing Phase 2 clinical trial with pipeline product MyeloXenā„¢ forĀ relapsing remitting and secondary progressive (SPMS) multiple sclerosis. The MyeloXen trial is currently underway in Russia with…

New Mouse Model Better Represents JC Virus That Infects MS Patients

Researchers in the laboratory of Steve Goldman, MD, PhD, Co-Director of University of Rochester Center for Translational Neuromedicine, are delving deeper into the science behind progressive multifocal leukoencephalopathy (PML), a disease caused by the JC virus, which commonly affects multiple sclerosis patients and others with compromised immune…

Major MS Cognitive Rehabilitation Trial Funded by British Health Service

TheĀ Cognitive Rehabilitation for Attention and Memory trial (CRAMMS), a major study to be conducted on patients suffering from multiple sclerosis, was recently awardedĀ Ā£1,167,000 ($1,828,000) by the British National Health ServiceĀ (NHS), through its Health Technology Assessment (HTA) Program. The study, which is expected to be the largest trial of its…

Individualized Multiple Sclerosis CE Plan Wins Excellence Award

The Alliance for Continuing Education in the Health Professions, an international membership association of healthcareĀ education professionals, has just selected the winner for theĀ 2015 Outstanding CE Enduring Material by the Alliance for Continuing Education in the Health Professions. The winner is a joint CE activity entitled, “Confronting Current Challenges…

‘Treat Me Right’ MS Society Campaign Shortlisted For Award

TheĀ Treat Me RightĀ campaign from the MSĀ SocietyĀ in the UK was recentlyĀ shortlistedĀ for this year’s voluntary sector campaignĀ Public Affairs Award. The campaign was launched in April 2014 during MS Week to raise awareness for the importance of providing the right treatment at the right moment…

Neurologist Recommends MS Approach Based on Alternative Medicine

Unconventional medical approaches and lifestyle changes may help patients suffering from multiple sclerosis (MS) improve their health and well-being, according toĀ Allen Bowling, MD, PhD, an internationally recognized neurologist and specialist in alternative medicine. The physician has designed a seven-step method based on his expertise, which is presented on his…

Genzyme’s Lemtrada Approved by the FDA

Cambridge, Massachusetts based Genzyme announced Friday that the U.S. Food and Drug Administration (FDA) has approved the company’s new drug Lemtrada (alemtuzumab) for treatment of people with relapsing forms of multiple sclerosis, which includes people who experience periodic MS attacks, such as those who have relapsing-remitting MS or secondary-progressive…

Sailboat Crewed by MS Patients Circumnavigating the Globe

Oceans of Hope, a 67-foot sail yacht currently docked at North Cove Marina, New York, is on a round-the-world voyage to become the first ship to ever circumnavigate with a crew of people who have Multiple Sclerosis. The voyage, initiated by Sailing Sclerosis Foundation, set sail from Copenhagen, Denmark…

Obesity Linked To Multiple Sclerosis?

A team of researchers at the Tel Aviv University report the role of obesity as a major risk factor triggering and maintaining autoimmune diseases, such as Crohn’s Disease and multiple sclerosis. The study was published in Autoimmunity Reviews. In autoimmune diseases, the immune system reacts against the body…

Teva and Active Biotech Expand Investigational MS Treatment Program

Drug manufacturersĀ Teva Pharmaceutical Industries Ltd.Ā and Active Biotech announced that they expanding the ongoing clinical research program for the study ofĀ laquinimod, a potential treatment for primary progressive multiple sclerosis (PPMS), as the companies are now initiating theĀ ARPEGGIO trial. In addition, Teva has also announced…

Genzyme Clinical Trial for Relapsing-Remitting MS Enrolls 1st Patient

Sanofi subsidiary and rare disease treatment specialistĀ GenzymeĀ has just announced the successful enrollment of the first participant in their multicenter Phase II clinical trial for the company’s pipeline intravenous drug forĀ relapsing-remitting multiple sclerosis (RRMS), vatelizumab. This novel drug is composed of humanized monoclonal antibodies that specifically target…